NVS Rasio rega marang prakiraan pendapatan novartis.com

Stable prescription drug sales guarantee Novartis AG (NVS) a reliable capital inflow, which is confirmed by the current forward P/S ratio. The value 3.00 reflects the current magnitude of this metric. Amid the struggle against generics and R&D expenditures, the company is optimizing its workforce while retaining key scientists to develop new molecules and maintain business competitiveness.

NVS Novartis Corporation: Rasio kapitalisasi pasar marang pendapatan mangsa ngarep ing interval 04.07.2022 - 13.11.2026

Rincian metrik lan analitis perusahaan Novartis Pharma (NVS)

- rega saiki lan proyeksi nilai saham:

Rega saham Novartis|NVS - Rentang target analis

- data kapitalisasi pasar:

Nilai pasar Novartis Pharma|NVS - Nilai Bisnis

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Novartis|NVS - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih novartis.com|NVS - Aset Agregat Perusahaan

- indikator total utang lan likuiditas perusahaan:

- data bathi bisnis lan rasio investasi:

NVS - Asil keuangan resik|Bathi mangsa ngarep Novartis AG|NVS - Nilai perusahaan marang bathi resik|Pangali Forward P/E Novartis Inc.|NVS - Pangali PEG|Pangali EV/EBITDA Novartis Pharma|NVS - Bathi operasional sadurunge potongan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Novartis|NVS - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan novartis.com|NVS - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Novartis AG

- rincian pendapatan lan dodolan:

NVS - Pendapatan reged perusahaan|Prakiraan pendapatan perusahaan Novartis|NVS - Rasio rega marang dodolan|Multiplikator Forward P/S Novartis Pharma

Ringkesan analisis perusahaan:Novartis (NVS)

The transformation of Novartis AG (NVS) into a specialized developer of high-margin biologics and gene therapies is altering its revenue structure. By analyzing the forward P/S trend, an investor compares the company's current market value with projected sales volumes. This ratio determines how much the market is willing to pay per unit of future revenue, confirming either the justification for a premium valuation of innovations or the overbought nature of the capital.

Perusahaan pesaing

Multiplikator Forward P/S LLY (Eli Lilly)|Prakiraan rega marang pendapatan AbbVie Inc|AZN - Rasio rega marang prakiraan pendapatan|MRK (MSD) - Kapitalisasi marang prakiraan pendapatan|Novo Nordisk A/S (NVO) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep amgen.com (AMGN)|Multiplikator forward rega marang pendapatan PFE|Rasio rega marang prakiraan pendapatan SNY|Multiplikator Forward P/S BMY|Multiplikator Forward P/S gsk.com (GSK)|Rasio rega marang prakiraan pendapatan Takeda Pharmaceutical TAK|Rega forward marang dodolan TEVA|RDY: Multiplikator forward rega marang pendapatan|Viatris Inc - Rasio rega marang pendapatan sing dikarepake|ROIV: Multiplikator Forward P/S|ZLAB - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Bausch Health Companies|cosmosholdingsinc.com (COSM) - Rasio kapitalisasi marang dodolan sing dikarepake